Canada markets close in 4 hours 20 minutes
  • S&P/TSX

    +162.68 (+0.82%)
  • S&P 500

    +31.77 (+0.78%)
  • DOW

    +225.02 (+0.68%)

    -0.0003 (-0.04%)

    +0.52 (+0.70%)
  • Bitcoin CAD

    +99.29 (+0.26%)
  • CMC Crypto 200

    +7.75 (+1.26%)

    -0.40 (-0.02%)
  • RUSSELL 2000

    +32.04 (+1.81%)
  • 10-Yr Bond

    -0.0340 (-0.96%)

    +124.14 (+1.03%)

    -0.20 (-1.05%)
  • FTSE

    +22.97 (+0.30%)
  • NIKKEI 225

    +258.55 (+0.93%)

    +0.0023 (+0.34%)

Enfusion (NYSE:ENFN) shareholders have endured a 55% loss from investing in the stock a year ago

Taking the occasional loss comes part and parcel with investing on the stock market. Unfortunately, shareholders of Enfusion, Inc. (NYSE:ENFN) have suffered share price declines over the last year. The share price is down a hefty 55% in that time. Enfusion may have better days ahead, of course; we've only looked at a one year period. More recently, the share price has dropped a further 29% in a month.

Since shareholders are down over the longer term, lets look at the underlying fundamentals over the that time and see if they've been consistent with returns.

See our latest analysis for Enfusion

Given that Enfusion didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. Shareholders of unprofitable companies usually expect strong revenue growth. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.

In the last twelve months, Enfusion increased its revenue by 38%. That's definitely a respectable growth rate. Meanwhile, the share price tanked 55%, suggesting the market had much higher expectations. It is of course possible that the business will still deliver strong growth, it will just take longer than expected to do it. To our minds it isn't enough to just look at revenue, anyway. Always consider when profits will flow.

The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).


You can see how its balance sheet has strengthened (or weakened) over time in this free interactive graphic.

A Different Perspective

Enfusion shareholders are down 55% for the year, even worse than the market loss of 23%. That's disappointing, but it's worth keeping in mind that the market-wide selling wouldn't have helped. The share price decline has continued throughout the most recent three months, down 28%, suggesting an absence of enthusiasm from investors. Given the relatively short history of this stock, we'd remain pretty wary until we see some strong business performance. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Case in point: We've spotted 1 warning sign for Enfusion you should be aware of.

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of companies that have proven they can grow earnings.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at)

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here